The prolactin receptor (PRLR) is expressed in a subset of breast cancers, and even at relatively low levels of expression, is constitutively internalised and rapidly trafficked to lysosomes for degradation, thus serving as a good therapeutic target for an ADC. This evidence concerns the gene PRLR and breast cancer.